Publications in collaboration with researchers from Mutua de Terrassa (8)

2026

  1. Aspirin Discontinuation at 24–28 Weeks and Placental Biomarker Trajectories: Post Hoc Analysis of a Randomised Trial

    BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 133, Núm. 3, pp. 432-441

  2. Prediction of preterm pre-eclampsia and preterm small-for-gestational-age at 24–28 weeks of gestation using ultrasound and biochemical markers in high-risk pregnancies treated with aspirin: A secondary analysis of the StopPRE trial

    International Journal of Gynecology and Obstetrics

2024

  1. Placental growth factor at 24–28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial

    Acta Obstetricia et Gynecologica Scandinavica, Vol. 103, Núm. 11, pp. 2273-2280

2016

  1. Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin

    European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 206, pp. 84-91

2015

  1. Asistencia a la gestante con diabetes. Guía de práctica clínica actualizada en 2014

    Avances en Diabetologia, Vol. 31, Núm. 2, pp. 45-59

2009

  1. Maternal glucose tolerance status influences the risk of macrosomia in male but not in female fetuses

    Journal of Epidemiology and Community Health, Vol. 63, Núm. 1, pp. 64-68

2005

  1. Body mass index has a greater impact on pregnancy outcomes than gestational hyperglycaemia

    Diabetologia, Vol. 48, Núm. 9, pp. 1736-1742

  2. Potential impact of American Diabetes Association (2000) criteria for diagnosis of gestational diabetes mellitus in Spain

    Diabetologia, Vol. 48, Núm. 6, pp. 1135-1141